EGFR and cholangiocarcinoma: Through the prediction and intersection of medicarpin-associated targets with CCA-related genes, the construction of protein–protein interaction networks, and the execution of pathway enrichment and molecular docking, we underscore critical oncogenic nodes, namely EGFR, mTOR, STAT3, and CCND1, that may facilitate the anti-CCA effects of medicarpin.